Physician profile
John R Dupre
NPI 1043222649
$4,981.14
in general payments reported to CMS, 2019-2025
27 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $471 · 2021: $739 · 2022: $464 · 2023: $664 · 2024: $792 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,525.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,017.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,013.86 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Grifols USA, LLC | $383.78 | 2019-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $183.67 | 2019 | |
| Insmed, INC. | $182.84 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $181.81 | 2019-2025 | |
| Vapotherm INC | $135.76 | 2019-2022 | |
| Baxter Healthcare | $125.33 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $125.04 | 2019-2024 | Yupelri |
| Verona Pharma, INC. | $92.35 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $70.55 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Shire North American Group INC | $64.56 | 2019 | |
| Inspire Medical Systems, INC. | $60.58 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.83 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $39.22 | 2025 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $33.84 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Fisher & Paykel Healthcare INC | $31.90 | 2023 | Fisher & Paykel Healthcare |
| Viatris Specialty LLC | $31.78 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $20.97 | 2024 | Glassia |
| Ani Pharmaceuticals, INC. | $20.81 | 2024 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $20.69 | 2021 | |
| Philips North America LLC | $19.08 | 2024 | (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $18.64 | 2019 | |
| Lilly USA, LLC | $14.68 | 2025 | Zepbound |
| Circassia INC. | $14.24 | 2019 | |
| Merck Sharp & Dohme LLC | $13.47 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dupre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.